|
Report No. : |
323489 |
|
Report Date : |
25.05.2015 |
IDENTIFICATION DETAILS
|
Name : |
SUN FARMACEUTICA DO BRASIL LTDA |
|
|
|
|
Registered Office : |
Rodvia Go 080, Km 02n S/N, Chac 01/02 Chs Retiro,0 - Zona Rural 74686-015 - Goiania/Go |
|
|
|
|
Country : |
Brazil |
|
|
|
|
Date of Incorporation : |
10.04.2002 |
|
|
|
|
Legal Form : |
Limited liability company |
|
|
|
|
Line of Business : |
Manufacture of medicines for human usage. |
|
|
|
|
No. of Employee : |
118 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Brazil |
A2 |
A2 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BRAZIL ECONOMIC OVERVIEW
Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly expanding middle class, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. Since 2008, Brazil became a net external creditor and all three of the major ratings agencies awarded investment grade status to its debt. After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. Unemployment is at historic lows and Brazil's traditionally high level of income inequality has declined for each of the last 15 years. Rising inflation led the authorities to take measures to cool the economy in 2011; these actions and the deteriorating international economic situation slowed growth in 2011-14. Brazil’s fiscal and current account balances have eroded during the past three years as the government attempted to boost economic growth through targeted tax cuts for industry and incentives to spur household consumption. President Dilma ROUSSEFF has indicated that her government in her second term will pursue more austere fiscal policies to reduce these imbalances and preserve the country’s credit rating.
|
Source
: CIA |
In absence of financials, no credit limit could be recommended.
SUN FARMACEUTICA DO BRASIL
LTDA
ADDRESSES
|
|
MAIN ADDRESS: |
RODVIA GO 080, KM
02N S/N, CHAC 01/02 CHS RETIRO,0 - ZONA RURAL |
|
ZIP CODE/CITY: |
74686-015 -
GOIANIA/GO |
|
|
|
|
PHONE: |
62 3205-2290 |
|
FAX: |
62 3205-2290 |
|
E-MAIL: |
|
BRANCHES: |
|
NOT AVAILABLE. |
LEGAL
DATA
|
|
MAIN ACTIVITIES: |
|
MANUFACTURE OF
MEDICINES FOR HUMAN USAGE. |
|
LEGAL FORM: |
LIMITED LIABILITY COMPANY |
|
|
|
|
INCORPORATION
DATE: |
10/04/2002 |
|
REGISTER DATE: |
25/04/2002 |
|
BALANCE SHEET
FILING DATE: |
31/12 |
|
TAX CONTRIBUTOR
NUMBER(CNPJ): |
05.035.244/0001-23 |
|
STATE REGISTER: |
103177736 |
|
|
|
|
SHARE CAPITAL: |
R$ 5.573.482,00 |
|
BOARD OF DIRECTORS: |
|
|
|
|
|
URVISH NARESKUMAR
BHAVSAR |
MANAGER |
|
DIGVIJAY SINGH |
MANAGER |
AUTHORIZED USE OF SIGNATURE
|
|
THE MANAGING
PARTNER ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY. |
|
SHAREHOLDERS / PARTNERS: |
|
|
|
|
|
ALKALOIDA
CHEMICAL COMPANY ZRT |
99,57% |
|
SUN PHARMA GLOBAL
INCORPORATED |
0,34% |
|
SUN
PHARMACEUTICAL INDUSTRIES LIMITED |
0,07% |
|
AFFILIATES / SUBSIDIARIES: |
|
|
|
|
|
NOT AVAILABLE. |
|
COMPANY'S
BACKGROUND
|
|
THE SUBJECT WAS ESTABLISHED
ON APRIL 10, 2002 AS "TKS FARMACEUTICA LTDA" TO BE ENGAGED IN THE
SAID LINE OF BUSINESS. IN DECEMBER /2014, IT ADOPTED THE ABOVE MENTIONED NAME
AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL SCENE REPORTED
HEREIN. FURTHER DETAILS
ARE SO FAR NOT KNOWN. REMARKS: -------- WHEN CONTACTING
THE SUBJECT WE INTERVIEWED MR AMANDA, FINANCIAL MANAGER, WHO INFORMED THAT
WOULD NOT DISCLOSE ANY KIND OF INFORMATION UNLESS THE INQUIRING PARTY'S NAME
WAS DISCLOSED. IF IT IS POSSIBLE
TO DISCLOSE THE NAME OF THE INTERESTED SUPPLIER OF THE SUBJECT, WE MAY RESUME
OUR CONTACTS AND TRY TO OBTAIN FURTHER INFORMATION. THE DATA
CONTAINED HEREIN WERE OBTAINED FROM OUTSIDE SOURCES, OUR DATABASE AND OFFICIAL.
NO FURTHER DATA WAS AVAILABLE WITH SEVERAL SOURCES USUALLY INVESTIGATED. |
|
PUBLIC INFORMATION: |
|
NO DETRIMENTAL
FILES WERE FOUND. |
FINANCIAL
INFORMATION
|
|
DUE TO THE SUBJECT'S
LEGAL FORM, IT IS NOT OBLIGED TO PUBLISH THE BALANCE SHEET INFORMATION. WHEN
INTERVIEWING SOURCES AT THE SUBJECT COMPANY DECLINED TO PROVIDE ANY KIND OF
FINANCIAL INFORMATION. OUTSIDE SOURCES
CONTACTED SHOWED NO FINANCIAL DATA ABOUT THIS COMPANY. |
|
EXCHANGE RATE: |
|
|
US$ 1,00 = R$
3,02 |
- OFFICIAL RATE ON 19/05/2015 |
|
COMMENTS ON THE FINANCIAL INFORMATION: |
|
IN THE ABSENCE OF
FINANCIAL INFORMATION NO COMMENTS CAN BE MADE ABOUT THE SUBJECT'S CURRENT
FINANCIAL STANDING. |
|
REAL ESTATE: |
NOT AVAILABLE
|
VEHICLES: |
NOT AVAILABLE
|
MACHINES: |
NOT AVAILABLE
INSURANCE
|
|
NOT AVAILABLE. |
BANKING
REFERENCES
|
|
|
|
|
|
NOT AVAILABLE. |
|
|
|
REMARKS: IN BRAZIL
THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF
COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO
PROVIDE ANY BANKING DETAILS. ACCORDING TO THE
CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS RETURNED CHECKS UP TO
DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK").
DATE RESEARCHED MAY 19, 2015. |
ACTIVITIES
COMMENTS
|
|
THE SUBJECT IS
ENGAGED IN THE MANUFACTURE OF MEDICINES FOR HUMAN USAGE. |
|
IMPORT AND EXPORT: |
IMPORTS
FROM:
|
NOT AVAILABLE. |
EXPORTS TO:
|
NOT AVAILABLE. |
|
MAIN CLIENTS: |
|
|
|
|
|
|
|
DOMESTIC CLIENTS: |
|
|
|
NOT AVAILABLE. |
|
|
|
STAFF: |
|
|
|
THE COMPANY HAS:
118 EMPLOYEE(S) |
CONCEPT
AND FULFILMENT
|
|
THE SUBJECT WAS ESTABLISHED
IN 2002. SO FAR IT HAS A CLEAR TRADE HISTORY AND NORMAL PAYMENT BEHAVIOR. THE COMPANY HAS
TRADE RELATIONS WITH SOME LOCAL SUPPLIERS BUT UP TO DATE ONLY SMALL PAYMENTS
WERE REPORTED AND THE SUBJECT IS NOT SAID TO BE USER OF TRADE CREDIT FACILITIES. |
|
MAIN SUPPLIERS: |
|
|
|
|
|
|
|
DOMESTIC SUPPLIERS: |
|
|
|
GOLDMAQ MEDICA
PROD. HOSPITALARES LTDA |
|
|
|
INDUKERN DO
BRASIL QUIMICA LTDA |
|
|
|
JC DIST. LOGIST.
EXP. PROD. HOSPITALARES LTDA |
|
|
|
STI COM. PROD.
FARAMAC. LTDA |
|
|
|
PAYMENT HISTORY |
|
11 SUPPLIERS
REPORTED PAYMENTS: |
|
TOTAL AMOUNT: R$ 71.829,00 |
|
|
|
AMOUNT OF
INVOICES PAID: 55 |
|
TOTAL OF PROMPT
PAYMENTS: 100% |
|
HIGHEST INVOICE:
R$ 4.712,00 |
|
HIGHEST CREDIT:
R$ 4.712,00 |
FINAL
OPINION
|
|
BASED ON THE OVERALL
DATA AVAILABLE THE SUBJECT MAY BE CONSIDERED FOR NORMAL BUSINESS COMMITMENTS.
CREDIT FACILITIES HOWEVER SHOULD BE GRANTED ON FULLY SECURED TERMS ONLY DUE
TO THE ABSENCE OF FINANCIAL DATA. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.70 |
|
|
1 |
Rs.98.92 |
|
Euro |
1 |
Rs.70.67 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.